Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs

Journal of Veterinary Internal Medicine

Volumn 22, Issue 1, 2008, Pages 164-171

  Flory, A B ^a   Rassnick, K M ^a,e   Al Sarraf, R ^b   Bailey, D B ^a,c   Balkman, C E ^a   Kiselow, M A ^a   Autio, K ^a,d  

^a Animal Health Diagnostic Center   (United States)

^b Animal Emergency and Referral Associates   (United States)

^c Long Island Veterinary Specialists   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e Department of Obstetrics Gynecology   (United States)

Author keywords

Cancer; Canine; Dacarbazine; Lomustine; Relapse; Rescue; Summation dose; Tolerable dose diagram

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 40549103821     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2007.0005.x     Document Type: Article

References (32)

1. 1 Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6‐month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002 ; 16: 704–709.
2. 2 Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12‐week, maintenance‐free combination chemotherapy protocol. J Vet Intern Med 2006 ; 20: 948–954.
3. 3 Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet Intern Med 1993 ; 7: 289–295.
4. 4 Khanna C, Lund EM, Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998 ; 213: 985–990.
5. 5 Chun R, Garrett LD, Vail DM. Evaluation of a high‐dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000 ; 14: 120–124.
6. 6 Boyce KL, Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000 ; 36: 395–403.
7. 7 Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA‐II) in dogs with lymphoma. J Vet Intern Med 1997 ; 11: 333–339.
8. 8 Moore AS, Leveille CR, Reimann KA, et al. The expression of P‐glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Invest 1995 ; 13: 475–479.
9. 9 Bergman PJ, Ogilvie GK, Powers BE. Monoclonal antibody C219 immunohistochemistry against P‐glycoprotein: Sequential analysis and predictive ability in dogs with lymphoma. J Vet Intern Med 1996 ; 10: 354–359.
10. 10 Lee JJ, Hughes CS, Fine RL, et al. P‐glycoprotein expression in canine lymphoma: A relevant, intermediate model of multidrug resistance. Cancer 1996 ; 77: 1892–1898.
11. 11 Tew KD, Colvin OM, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed. Philadelphia: Lippincott, Williams & Wilkins ; 2001: 374–414.
12. 12 Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999 ; 13: 395–398.
13. 13 Lemarié SL, Eddlestone SM. Treatment of cutaneous T‐cell lymphoma with dacarbazine in a dog. Vet Dermatol 1997 ; 8: 41–46.
14. 14 Gray KN, Raulston GL, Gleiser CA, et al. Histologic classification as an indicator of therapeutic response in malignant lymphoma in dogs. J Am Vet Med Assoc 1984 ; 184: 814–817.
15. 15 Van Vechten M, Helfand SC, Jeglum KA. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine. J Vet Intern Med 1990 ; 4: 187–191.
16. 16 Simon R, Korn EL. Selecting drug combinations based on total equivalent dose (dose intensity). J Natl Cancer Inst 1990 ; 82: 1469–1476.
17. 17 Korn EL, Simon R. Using the tolerable‐dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol 1993 ; 11: 794–801.
18. 18 Veterinary co‐operative oncology group common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004 ; 2: 195–213.
19. 19 Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999 ; 13: 601–605.
20. 20 Fan TM, Kitchell BE. Dacarbazine. Comp Contin Ed 2000 ; 22: 1020–1023.
21. 21 Day RS. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986 ; 46: 3876–3885.
22. 22 Frei E III, Elias A, Wheeler C, et al. The relationship between high‐dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998 ; 4: 2027–2037.
23. 23 Boyer MJ, Tannock IF. Cellular and molecular basis of drug treatment for cancer. In: Tannock IF, Hill RP, Bristow RG, Harrington L, eds. The Basic Science of Oncology, 4th ed. New York: McGraw‐Hill ; 2005: 349–375.
24. 24 LeBlanc A, Mauldin G, Milner R, et al. Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma. Vet Compar Oncol 2006 ; 4: 21–32.
25. 25 Saba CF, Thamm DH, Vail DM. Combination chemotherapy with l‐asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med 2007 ; 21: 127–132.
26. 26 Hahn KA, Barnhill MA, Freeman KP, et al. Detection and clinical significance of plasma glutathione‐ S ‐transferases in dogs with lymphoma. In Vivo 1999 ; 13: 173–175.
27. 27 Morrison‐Collister KE, Rassnick KM, Northrup NC, et al. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP‐SC) for the treatment of canine lymphoma. Vet Compar Oncol 2003 ; 1: 180–190.
28. 28 Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006 ; 20: 136–143.
29. 29 Risbon RE, De Lorimier LP, Skorupski K, et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999–2004). J Vet Intern Med 2006 ; 20: 1389–1397.
30. 30 Kristal O, Rassnick KM, Gliatto JM, et al. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. J Vet Intern Med 2004 ; 18: 75–80.
31. 31 Trepanier LA, Danhof R, Toll J, et al. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 2003 ; 17: 647–652.
32. 32 Skorupski KA, Clifford CA, Paoloni MC, et al. CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med 2007 ; 21: 121–126.